Name

MINE-ESHAP

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for MINE-ESHAP

Name

Alternate Names

CL 232315
Mitoxantrone Hydrochloride
Mitozantrone
Novantrone

Abbreviations

DAD
DHAD
DHAQ

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

301739

Primary Site

Breast
Non-Hodgkin lymphoma
Prostate- advanced hormone-refractory

Histology

None

Remarks

Antibiotic-class antineoplastic. FDA approved uses in adult acute non-lymphocytic leukemia, and prostate cancer pain reduction in combination with prednisone. Novantrone is a synthetic antineoplastic anthracenedione

Coding

This drug should be coded

Name

Alternate Names

Dom-Etoposide
Epipodophyllotoxin derivative
Epipodophyllotoxin ethylidene gluco-pyranoside
Eposine
Ethylidene-Lignan P
Etopophos
Podophyllotoxin derivative
Vepesid
VP 16-213
VP-16
VP-16213
Toposar

Abbreviations

EPEG
VP-16
VP-16-213

Category

Chemotherapy

Subcategory

Epipodophyllotoxin, topoisomerase II inhibitor
Plant alkaloid

NSC Number

141540

Primary Site

Gastric cancer
Hodgkins lymphoma
Lung cancer (NSCLC, SCLC)
Non-Hodgkin lymphoma
testicular cancer (Germ cell tumors)

Histology

None

Remarks

Plant alkaloid. FDA approved use on small-cell lung cancer, testicular cancer.

Coding

This drug should be coded

Name

Alternate Names

A-Methapred
Cordex Forte
Depmedalone
Depo-Medrol
Depo-Predate
Depoject
Depopred
Dopmedrol
Enpak Refill
Mar-Pred
Medrate
Medrol
Medrone
Methyl Prednisolone
Methylone
Pre-Dep
Promacortine
Rep-Pred
Urbason

Abbreviations

None

Category

Hormones and hormonal mechanisms

Subcategory

Glucocorticoid

NSC Number

019987
19987

Primary Site

None

Histology

None

Remarks

Code this drug as hormone therapy when given in multi-drug regimens.

Coding

This drug should be coded

Name

Alternate Names

D 7093
Mesna rescue
Mesnex
Mesnex uroprotection
Mesnum
Mistabron
Mitexan
Mucofluid
Sodium 2-mercaptoethanolsulfonate
UCB 3983
Uromitexan

Abbreviations

None

Category

Ancillary Agent

Subcategory

None

NSC Number

113891

Primary Site

None

Histology

None

Remarks

A prophylactic detoxifying agent used to inhibit hemorrhagic cystitis caused by ifosfamide. FDA approved for bladder protection when using cyclophosphamide (prevents bladder toxicity).

Coding

This drug should NOT be coded

Name

Alternate Names

Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum

Abbreviations

CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP

Category

Chemotherapy

Subcategory

Alkylating agent
Platinum analog

NSC Number

119875

Primary Site

Bladder
ovarian
testicular cancer

Histology

None

Remarks

An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.

Coding

This drug should be coded

Name

Alternate Names

A-4942
Asta Z-4942
Cyfos#
Holoxan 1000
Ifex
Ifosfamid
Ifoxan
Iphosphamid
Iphosphamide
Iso-endoxan
Isofosfamide
Isophos-phamide
Isophosphamide
Mitoxana
MJF 9325
MJF-9325
Naxamide#
Z4942

Abbreviations

IFX
IPP

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

109724

Primary Site

Bladder
Cervical cancer
Ewing sarcoma
Head and Neck
Hodgkin lymphoma
Non-Hodgkin lymphoma
Non-small cell and small cell lung cancer
Soft tissue sarcoma, osteogenic sarcoma
Testicular cancer

Histology

None

Remarks

Antineoplastic with alkylating activity. FDA approved.

Coding

This drug should be coded

Name

Alternate Names

AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453

Abbreviations

ara-C
CA
HDA
HDARA-C

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

063878
63878

Primary Site

ALL
AML
CML
head and neck
Hodgkin's disease
leukemia
Meningeal leukemia
NHL

Histology

None

Remarks

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

Coding

This drug should be coded
Glossary